ANI ‘On The Cusp Of A Transformation’ Following Cortrophin Launch
Company Expects Up To $40m From The Product In 2022
ANI Pharmaceuticals appeared confident about its Cortrophin gel launch and integration of Novitium Pharma as it rounded up its Q1 results, but net losses have dampened the company’s share value.
You may also be interested in...
ANI Pharmaceuticals has announced the closure of its Oakville, Ontario manufacturing plant, a move which is expected to save the firm $7m to $8m.
ANI Pharmaceuticals has finally delivered its long-awaited launch of purified Cortrophin Gel (repository corticotropin injection) in the US, accompanying the launch with its ‘Cortrophin In Your Corner’ dedicated program to increase access and provide reimbursement support.
ANI Pharmaceuticals has completed its acquisition of niche generics specialist Novitium Pharma, securing access to a pipeline of generics and 505(b)(2) candidates that has expanded further since the deal was announced earlier in the year.